GlassScriptPhysician profile
Lei T Win
NPI 1124436001
$1,413.76
in general payments reported to CMS, 2019-2025
12 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $359 · 2022: $532 · 2023: $215 · 2024: $82.60 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $398.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gastroklenz, INC. Dba Cloudcath | $400.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $186.61 | 2021-2024 | |
| Aurinia Pharma U.S., INC. | $154.28 | 2021-2023 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $129.04 | 2021-2025 | Farxiga, Lokelma |
| Alexion Pharmaceuticals, INC. | $116.22 | 2020-2021 | |
| Veloxis Pharmaceuticals, INC. | $112.29 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $112.29 | 2021-2024 | Jynarque |
| Novartis Pharmaceuticals Corporation | $108.65 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $30.75 | 2022 | |
| Amgen INC. | $23.38 | 2023 | Tavneos |
| Mallinckrodt Hospital Products INC. | $21.79 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lei Win listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.